Abstract 2620
Background
Absenteeism and presenteeism (A/P) are scales related to health problems and professional activity in patients and in healthy individuals. For cancer patients in the age of maximum labor productivity (18 to 65 years old), A/P are possibly affected by quality of care, type of cancer, and selection of treatments. The objectives of this study were to clarify via questionnaire the association between quality-of-life (QOL) and A/P, as well as the changes of A/P during clinical course in cancer patients.
Methods
A/P were measured using the validated Japanese version of the World Health Organization Health and Work Performance Questionnaire (WHO-HPQ). QOL was measured using the 5-level EQ-5D version via a portable device with the Apple ResearchKit app.
Results
We received 3983 survey results (healthy individuals, 297; cancer patients, 3686). Presenteeism was clearly different between cancer patients and healthy individuals (absolute/relative presenteeism: 59.3/0.93 and 65.8/1.01, respectively). Examination of the relationship between QOL and A/P using Spearman’s rank correlation coefficient analysis indicated that QOL is significantly correlated with relative presenteeism (r = 0.40, P < 0.001). The labor performance of pancreatic carcinoma patients was low (absolute/relative absenteeism: 68.7/0.29, absolute/relative presenteeism: 43.8/0.68). The A/P in patients with receiving chemotherapy were not maintained compared to in patients receiving surgical treatment (absolute/relative absenteeism: 39/8/0.16 vs. 17.8/0.02, p = 0.04, absolute/relative presenteeism: 55.5/0.83 vs. 62.8/0.95, p < 0.001, respectively).
Conclusions
WHO-HPQ can be used to measure the labor performance in cancer patients. Moreover, A/P was strongly affected by type of cancers and selection of treatments.
Clinical trial identification
Editorial acknowledgement
The research was supported by Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Legal entity responsible for the study
Shunsuke Kondo.
Funding
Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract